Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5943295 | 0.83 | ALDH1A1 (0.50) | RAB9ANPC1PDE4DMAPTL3MBTL1 | |
| SCHEMBL5943286 | 0.83 | PARP1 (0.44) | RAB9ANPC1GRM4KDRGRM5 | |
| SCHEMBL5455921 | 0.82 | RAB9A (0.48) | RAB9ANPC1GRM4MAPTL3MBTL1 | |
| SCHEMBL5452893 | 0.81 | NOTUM (0.31) | KDR | |
| SCHEMBL5452890 | 0.81 | NOTUM (0.31) | KDR | |
| SCHEMBL19203282 | 0.78 | CA12 (0.43) | RAB9ANPC1CA12CA1CA2 | |
| SCHEMBL5943201 | 0.77 | SMN1; SMN2 (0.46) | GRM5MAPT | |
| SCHEMBL5349959 | 0.77 | RAB9A (0.59) | RAB9ANPC1HSD11B1PTPN1MAPT | |
| SCHEMBL5943173 | 0.75 | ALDH1A1 (0.42) | RAB9ANPC1GRM4PTPN1MAPT | |
| SCHEMBL5209337 | 0.75 | RAB9A (0.49) | RAB9ANPC1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | BOYD F LESLIE | 2007-12-13 | — | — | US | disclosed |
| US-7163940-B2 | Pyrazolopyridinyl pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-16 | — | — | US | disclosed |
| US-20060293344-A1 | Therapeutic Compounds | BOYD F L | 2006-12-28 | — | — | US | disclosed |
| US-7153855-B2 | Pyrazolopyridinyl pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1377573-B1 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2005-07-27 | — | — | EP | disclosed |
| US-20050049260-A1 | Therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-03-03 | — | — | US | disclosed |
| US-20050049259-A1 | Theraopeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-03-03 | — | — | US | disclosed |
| EP-1366048-B1 | PYRAZOLOPYRIDINE DERIVATIVES | SMITHKLINE BEECHAM CORP (US) | 2004-08-25 | — | — | EP | disclosed |
| EP-1377573-A2 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-01-07 | — | — | EP | disclosed |
| EP-1366048-A2 | PYRAZOLOPYRIDINE DERIVATIVES | SmithKline Beecham Corporation (US) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072581-A2 | PYRAZOLOPYRIADINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002048148-A2 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049259-A1 | Theraopeutic compounds | PCSK9, FOLH1, EPHA2 | RAB9A 2333/4885NPC1 205/4885GRM4 2429/4885 |
| US-20060293344-A1 | Therapeutic Compounds | PCSK9, ABCB1, ABCB11 | RAB9A 1243/4885NPC1 6/4885GRM4 3071/4885 |
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | CYP3A5, CYP2C19, CYP3A4 | RAB9A 1326/4885NPC1 1177/4885GRM4 3798/4885 |
| US-20050049260-A1 | Therapeutic compounds | ABCB1, PCSK9, ABCB11 | RAB9A 1242/4885NPC1 8/4885GRM4 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.